A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer (NCT06966453)
A PHASE 1b/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have breast cancer that is hard to treat and has spread in the body (advanced cancer) * have tumors that have HER2 on them * have received previous treatment for their advanced breast cancer All participants in this study will receive disitamab vedotin at the study clinic once every 2 weeks as an intravenous (IV) infusion (given directly into a vein). Participants will take the study medicine until they or their doctor decides to stop. This might be because their cancer is getting worse, the study medicine is no longer helping, they have bad side effects, or they wish to stop taking the study medicine. During this time, the participants will have study visits every 2 weeks. After the participants have stopped taking the study medicine, they will have follow-up visits about every 6 weeks unless their cancer gets worse. After that, they will have follow-up phone calls about every 12 weeks. The study team will look at the experiences of people receiving the study medicine. This will help the study team decide if the study medicine is safe and effective.
Who can join: Review the eligibility criteria below.
Location: Southern Cancer Center, PC — Daphne, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (166 Sites)
Showing the first 25 of 166 sites.
- Southern Cancer Center, PC — Daphne, Alabama
- Southern Cancer Center, PC — Foley, Alabama
- Southern Cancer Center, PC — Mobile, Alabama
- Banner Gateway Medical Center — Gilbert, Arizona
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Los Angeles Cancer Network - Anaheim — Anaheim, California
- City of Hope National Medical Center — Duarte, California
- Los Angeles Cancer Network — Fountain Valley, California
- Los Angeles Hematology Oncology Medical Group — Glendale, California
- City of Hope at Irvine Lennar — Irvine, California
- Los Angeles Cancer Network — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Mission Community Hospital (Satellite Site) — Los Angeles, California
- Clinical and Translational Research Unit (CTRU) — Palo Alto, California
- Stanford Cancer Center — Palo Alto, California
- Stanford Women's Cancer Center — Palo Alto, California
- Stanford Health Care, Investigational Drug Service — Stanford, California
- Los Angeles Hematology Oncology Medical Group — Van Nuys, California
- Rocky Mountain Cancer Centers, LLP — Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP — Boulder, Colorado
- Rocky Mountain Cancer Centers, LLP — Centennial, Colorado
- Rocky Mountain Cancer Centers, LLP — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers, LLP — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers, LLP — Denver, Colorado
- Rocky Mountain Cancer Centers, LLP — Englewood, Colorado
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.